BeStock  
Stocks › Biotechnology › FDMT

4D Molecular Therapeutics FDMT

US equityMarket cap rank #3512Biotechnology
$10.23 −$0.49 (-4.57%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.23 0.00%
Open$10.36
Prev close$10.72
Day range$10.11 – $10.94
Volume691.0K
Market cap$576.76M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$4.15M+4,505.6% YoY
Operating profit-$81.22M-32.7% YoY
Net profit-$78.06M-37.2% YoY
Diluted EPS-$1.08-6.9% YoY
Free cash flow-$56.76M-22.3% YoY
Operating cash flow-$56.71M

Revenue, last 8 quarters

$1,000Dec '24$14.0KMar '25$15.0KJun '25$90.0KSep '25$85.1MDec '25$3.0MMar '26$3.8MJun '26$4.1MSep '26

Net profit, last 8 quarters

$-49.7MDec '24$-48.0MMar '25$-54.7MJun '25$-56.9MSep '25$19.4MDec '25$-68.8MMar '26$-72.9MJun '26$-78.1MSep '26

Diluted EPS by quarter

-0.90Dec '24-0.86Mar '25-0.98Jun '25-1.01Sep '250.43Dec '25-1.01Mar '26-1.04Jun '26-1.08Sep '26

Free cash flow by quarter

$-46.8MDec '24$-48.4MMar '25$-43.4MJun '25$-46.4MSep '25$28.6MDec '25$-68.1MMar '26$-70.1MJun '26$-56.8MSep '26

Annual revenue

$13.6MFY20$18.0MFY21$3.1MFY22$20.7MFY23$37.0KFY24$85.2MFY25

Profitability & balance sheet

Operating margin-226.0%
Net margin-208.6%
Return on equity-56.7%
Return on assets-47.0%
Return on invested capital-56.8%
Current ratio6.15
Liabilities / assets21.2%
Cash & investments$306.99M
Total debt$33.10M
Net cash (debt)$273.89M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $4.15M $3.78M $3.05M $85.21M $85.09M
Total Operating Revenue $4.15M $3.78M $3.05M $85.21M $85.09M
Operating Expense $85.36M $80.81M $76.67M $244.76M $70.38M
Selling and Admin Expenses $15.59M $12.52M $11.69M $49.06M $12.77M
-General & Admin Expense $15.59M $12.52M $11.69M $49.06M $12.77M
Research & Development $69.78M $68.28M $64.98M $195.70M $57.61M
Operating Profit -$81.22M -$77.03M -$73.62M -$159.55M $14.72M
Net Non-Operating Interest Income (Expense) $3.94M $4.26M $4.86M $19.48M $4.70M
Non-Operating Interest Income $3.94M $4.26M $4.86M $19.48M $4.70M
Other Income (Expense) -$781,000.00 -$166,000.00 -$4,000.00 -$37,000.00 -$22,000.00
Other Non-Operating Income (Expenses) -$781,000.00 -$166,000.00 -$4,000.00 -$37,000.00 -$22,000.00
Pretax Profit -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Net Profit -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Profit from Continuing Operations -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Net Income to Parent Company -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Net Income to Common Stockholders -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Basic EPS -$1.08 -$1.04 -$1.01 -$2.42 $0.43
Diluted EPS -$1.08 -$1.04 -$1.01 -$2.42 $0.43

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $428.75M $492.62M $512.91M $566.71M $566.71M
Total Current Assets $322.29M $382.96M $405.36M $413.13M $413.13M
Cash and Cash Equivalents & Short-Term Investments $306.99M $361.33M $390.89M $402.66M $402.66M
-Cash and Cash Equivalents $39.10M $70.37M $72.49M $60.24M $60.24M
-Short Term Investments $267.89M $290.96M $318.40M $342.41M $342.41M
Receivables $4.02M $4.61M – – –
-Other Receivables $4.02M $4.61M – – –
Other Current Assets $11.28M $17.01M $14.47M $10.48M $10.48M
Total Non-Current Assets $106.46M $109.66M $107.54M $153.58M $153.58M
Net PPE $26.98M $28.93M $30.94M $33.01M $33.01M
-Gross PPE $51.32M $52.37M $53.49M $54.29M $54.29M
-Accumulated Depreciation -$24.34M -$23.44M -$22.55M -$21.28M -$21.28M
Investments and Advances $68.04M $69.30M $66.74M $111.38M $111.38M
-Available for Sale Securities $68.04M $69.30M $66.74M $111.38M $111.38M
Other Non-Current Assets $11.44M $11.44M $9.86M $9.19M $9.19M
Total Liabilities $90.81M $84.96M $61.07M $61.05M $61.05M
Total Current Liabilities $52.39M $47.67M $43.40M $43.99M $43.99M
Payables $7.88M $12.52M $14.69M $11.16M $11.16M
-Accounts Payable $7.88M $12.52M $14.69M $11.16M $11.16M
Current Accrued Expenses $35.21M $25.43M $22.87M $26.87M $26.87M
Short-Term Debt and Capital Lease Obligation $5.31M $5.37M $5.49M $5.59M $5.59M
-Current Capital Lease Obligation $5.31M $5.37M $5.49M $5.59M $5.59M
Current Deferred Liabilities $3.99M $4.35M $360,000.00 $360,000.00 $360,000.00
Total Non-Current Liabilities $38.41M $37.28M $17.67M $17.06M $17.06M
Long Term Debt and Capital Lease Obligation $33.10M $33.84M $15.05M $15.82M $15.82M
-Long Term Debt $19.68M $19.59M – – –
-Long Term Capital Lease Obligation $13.42M $14.26M $15.05M $15.82M $15.82M
Derivative Product Liabilities $397,000.00 $384,000.00 $370,000.00 $358,000.00 $358,000.00
Non-Current Deferred Liabilities $2.83M $2.96M $2.13M $745,000.00 $745,000.00
Other Non-Current Liabilities $2.08M $101,000.00 $121,000.00 $138,000.00 $138,000.00
Total Equity $337.94M $407.66M $451.84M $505.66M $505.66M
Stockholders' Equity $337.94M $407.66M $451.84M $505.66M $505.66M
Capital Stock $6,000.00 $6,000.00 $5,000.00 $6,000.00 $6,000.00
-Common Stock $6,000.00 $6,000.00 $5,000.00 $6,000.00 $6,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.27B $1.27B $1.24B $1.22B $1.22B
Retained Earnings -$936.06M -$858.00M -$785.06M -$716.30M -$716.30M
Gains/Losses Not Affecting Retained Earnings -$1.01M -$446,000.00 -$180,000.00 $727,000.00 $727,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$56.71M -$70.00M -$68.13M -$109.08M $28.55M
Net cash flow from continuing operations -$56.71M -$70.00M -$68.13M -$109.08M $28.55M
Net Income from Continuing Operations -$78.06M -$72.94M -$68.76M -$140.11M $19.40M
Gain/Loss from Continuing Operations $21,000.00 $57,000.00 $12,000.00 -$52,000.00 $13,000.00
Depreciation & Depletion & Amortization $2.01M $2.09M $2.06M $7.63M $1.98M
Change in Working Capital $12.09M -$4.10M -$4.75M $6.17M $2.76M
-Change in Prepaid Assets $6.04M -$6.53M -$3.99M -$424,000.00 -$3.17M
-Change in Payables and Accrued Expense $8.48M $2.49M -$590,000.00 $14.93M $6.67M
-Change in Other Current Assets -$1.42M $18,000.00 -$670,000.00 -$4.93M $192,000.00
-Change in Other Current Liabilities -$896,000.00 -$905,000.00 -$878,000.00 -$3.19M -$850,000.00
-Change In Other Working Capital -$125,000.00 $830,000.00 $1.38M -$209,000.00 -$90,000.00
Net cash flow from investing $24.84M $25.54M $68.89M -$92.97M -$128.85M
Net Cash Flow from Continuing Investing Activities $24.84M $25.54M $68.89M -$92.97M -$128.85M
Net PPE Purchase and Sale -$49,000.00 -$66,000.00 $11,000.00 -$536,000.00 $70,000.00
Net Investment Purchase and Sale $24.89M $25.61M $68.88M -$92.44M -$128.92M
Financing Cash Flow $604,000.00 $42.34M $11.48M $112.96M $111.98M
Net Cash Flow from Continuing Financing Activities $604,000.00 $42.34M $11.48M $112.96M $111.98M
Net Issuance Payments Of Debt $0.00 – – – –
Net Common Stock Issuance -$38,000.00 $21.84M $9.81M $110.72M $110.72M
Proceeds from Stock Option Exercised $642,000.00 $1.24M $1.67M $2.24M $1.26M
Ending Cash Balance $39.10M $70.37M $72.49M $60.24M $60.24M
Net Change in Cash -$31.27M -$2.12M $12.25M -$89.10M $11.69M
Beginning Cash Balance $70.37M $72.49M $60.24M $149.34M $48.56M
Free Cash Flow -$56.76M -$70.05M -$68.13M -$109.62M $28.62M

Discussion

No comments yet — be the first to weigh in on FDMT.

Sign in to join the discussion.

Scroll to Top